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Respiratory failure in pulmonary
hypertension patients
pulmonary  artery  systolic  pressure  on  the  last  echocardio-
































Fernanda  Paula,  Paula  Pinto  and  Filipe  Froes  participated
in  the  clinical  management  of  the  patients.  Miguel  FilipeInsuficiência respiratória na hipertensão
pulmonar
To  the  Editor:
Management  of  respiratory  failure  (RF)  in  pulmonary  hyper-
tension  (PH)  is  a  complex  subject,  since  positive  pressure
ventilation  (PPV)  can  reduce  right  ventricular  (RV)  output.1,2
During  PPV  there  is  an  increase  in  intrathoracic  pres-
sure,  increasing  right  atrial  pressure.1 This  leads  to  lower
venous  return  and  consequently  to  decreased  RV  preload  and
output.1 Furthermore,  pulmonary  vascular  resistance  (PVR),
the  main  determinant  of  RV  afterload,  is  directly  affected
by  changes  in  lung  volume,  since  when  the  lung  is  hyper-
inflated,  alveolar  distension  occurs,  leading  to  compression
of  the  alveolar  vessels.1,2 On  the  other  hand,  low  lung
volumes  result  in  terminal  airway  collapse  and  hypoxic  vaso-
constriction,  and  parenchymal  vessels  also  become  more
tortuous  and  predisposed  to  collapse.1,2 All  the  above  factors
tend  to  reduce  left  ventricular  output,  leading  to  systemic
hypotension.
Protective  ventilation  may  reduce  the  negative  effects  of
significant  changes  in  lung  volume.2,3
Epoprostenol  is  a  potent  vasodilator  that  is  used  in  more
severe  cases  of  PH.  One  of  its  main  side  effects  is  systemic
hypotension,  which  can  be  enhanced  by  PPV,  as  previously
described.4
Santos  et  al.  recently  showed  that  parenteral  prostanoids
are  underused  in  group  1  PH,  in  only  20%  of  PH  patients  at  the
time  of  death  in  their  study.5 As  RF  is  an  important  concern
in  advanced  PH,  we  conducted  a  retrospective  analysis  of
RF  treatment  and  its  impact  in  advanced  PH  patients  who
began  epoprostenol  as  salvage  therapy  in  the  intensive  care
unit  of  Centro  Hospitalar  Universitário  Lisboa  Norte,  Lisbon,
Portugal,  over  a  two-year  period.
Ten  patients  were  included,  mean  age  65  years,  50%
female.
Six  patients  had  group  1  PH  (four  idiopathic  PH,  one
congenital  heart  disease  and  one  associated  with  schis-
tosomiasis),  and  four  had  group  4  PH.  All  presented
mean  pulmonary  artery  pressure  over  35  mmHg  on  right
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unctional  class  IV,  with  worsening  RF,  and  most  (60%)  were
n  long-term  oxygen  therapy.
Previous  medication  included  ambrisentan  (four
atients),  bosentan  (three),  macitentan  (two),  silde-
afil  (five)  and  riociguat  (four).  Epoprostenol  was  initiated
s  salvage  therapy  and  dosages  were  titrated  to  ≥11
g/kg/min  in  six  patients.
Initially,  partial  RF  was  present  in  eight  patients  and  the
ther  two  rapidly  developed  general  RF.  Three  of  the  par-
ial  RF  patients  required  high-flow  oxygen  therapy  (HFOT)
ith  flow  50  l/min  and  fraction  of  inspired  oxygen  100%.  The
wo  patients  with  general  RF  began  non-invasive  ventilation
NIV)  and  were  titrated  to  inspiratory  positive  airway  pres-
ure  (IPAP)  30  cmH2O  and  expiratory  positive  airway  pressure
EPAP)  10  cmH2O  in  one,  and  IPAP  24  cmH2O  and  EPAP  12
mH2O  in  the  other  (this  patient  alternated  NIV  with  HFOT).
There  were  four  deaths,  three  due  to  hemodynamic  col-
apse  and  one  due  to  nosocomial  infection.  All  of  these
our  patients  had  group  1  PH.  It  was  not  possible  to
itrate  epoprostenol  dosage  to  11  ng/kg/min  in  three  of  the
atients  who  died.  The  two  patients  who  were  on  NIV  died,
s  did  two  of  the  patients  on  HFOT  due  to  progression  of
artial  RF.
This  study  illustrates  the  limitations  of  RF  treatment  in
atients  with  PH  on  epoprostenol  therapy,  particularly  those
n  NIV  (due  its  deleterious  hemodynamic  effects  on  already
ypotensive  patients).  In  fact,  all  patients  on  NIV  died,  prob-
bly  due  to  underlying  disease,  severity  of  RF  and  worsening
f  RV  failure  due  to  increased  positive  airway  pressure.  Of
he  three  patients  who  were  only  on  HFOT,  only  one  sur-
ived,  but  HFOT  may  be  an  interesting  option  in  PH  patients,
specially  at  the  beginning  of  RF  development.  More  studies
re  needed  to  validate  the  possible  usefulness  of  HFOT  in  PH
nd  to  establish  an  appropriate  NIV  management  approach,
n  particular  the  use  of  protective  ventilation.
uthorshipuia  analyzed  patients’  clinical  data,  particularly  on  clas-
ification  of  pulmonary  hypertension,  oxygen  and  ventilator
























trategies,  and  their  outcomes.  Miguel  Filipe  Guia  also  per-
ormed  a  short  review  of  respiratory  failure  management  in
ulmonary  hypertension  and  interpreted  the  results  based
n  that  review.  Fernanda  Paula,  Paula  Pinto  and  Filipe  Froes
articipated  in  the  revision  of  the  present  work.
The  present  letter  has  four  authors  since  all  four  made
ssential  contributions  to  it.
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